Introduction: Tocilizumab (TCZ), an anti-interleukin-6 receptor antibody, is clinically effective against rheumatoid arthritis (RA), and several reports have indicated how TCZ influences a number of mechanisms underlying RA pathogenesis. However, it is still unclear whether TCZ affects inflammatory cells in peripheral blood and whether any such changes are associated with clinical response. We evaluated associations between proportions of subsets of peripheral immune cells and clinical response in patients with RA treated with TCZ.
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Introduction
T cells (especially CD4 + T cells), monocytes and B cells are considered to be involved in the pathogenesis of rheumatoid arthritis (RA) [1] . It is frequently considered that decreasing the number and/or activity of lymphocytes and other immune cells by RA treatment can reduce disease activity. The first evidence of this was seen in preliminary clinical trials in which targeting CD4 + T cells with anti-CD4 monoclonal antibodies (mAbs) resulted in clinical improvement of RA, albeit only modestly [2] . Abatacept, a cytotoxic T lymphocyte antigen 4 immunoglobulin recombinant fusion protein that inhibits CD4 + T cell activation by blocking costimulation with antigen-presenting cells such as B cells and monocytes, showed clinical efficacy against RA and has been approved worldwide for the treatment of RA [3] . Depletion of peripheral B cells by the anti-CD20 antibody rituximab also improves disease activity [4] .
The anti-interleukin-6 receptor (IL-6R) antibody tocilizumab (TCZ) is also clinically effective against RA [5] . Several studies have shown that blocking the IL-6 signaling with TCZ can affect proportions of peripheral blood cells. Given that IL-6 was originally identified as a B cell differentiation factor [6, 7] , it is not surprising that TCZ affects proportions of B cell populations in patients with RA. IL-6 also influences differentiation of T cells into effector T cells (T H 1, T H 2 and T H 17 cells) or regulatory T cells (T reg ) [8] [9] [10] . In recent studies, researchers have shown that IL-6 blockade could favorably affect the T H 17/T reg cell imbalance in patients with RA [11, 12] . Moreover, IL-6 seems to affect the proliferation and activation of monocytes that express IL-6R [13, 14] . However, because in previous studies the number of patients, the period of study and the examined cell populations were limited, it is not clear whether there is a key population of peripheral immune cells that attenuates RA clinical symptoms through anti-IL-6R therapies [11, 12, 15] . If these relationships could be clarified, it would enable medical researchers to comprehend the pathogenesis of RA from the view of lymphocyte populations and to find surrogate markers in order to choose an optimal therapeutic strategy for RA.
The primary objective of this study was to evaluate multiple different types of peripheral blood cells by using flow cytometry analysis to identify populations modulated by anti-IL-6R therapy. The secondary objective was to determine whether any of these populations is strongly associated with various clinical measures in response to anti-IL-6R therapy.
Methods

Patients
Eligible patients were those who met the 1987 revised criteria of the American College of Rheumatology (ACR) for the classification of RA or the 2010 ACR/European League Against Rheumatism (EULAR) classification criteria [16, 17] . Consecutive patients at our institute who commenced TCZ as their first biologic agent between March 2010 and April 2012 were enrolled. They all showed insufficient response to at least one conventional synthetic disease-modifying antirheumatic drug (csDMARD). The enrolled patients were administered 8 mg/kg TCZ every 4 weeks, either with or without other csDMARDs, including methotrexate (MTX). The study protocol was approved by the ethics committee at Keio University School of Medicine and was carried out in accordance with the Declaration of Helsinki and Good Clinical Practice. Written informed consent was obtained from all patients.
Clinical assessments and evaluation of effectiveness
Demographic and clinical characteristics including age, sex, disease duration, tender joint count (TJC), swollen joint count (SJC), patient global assessment (patient visual analogue scale (Pt-VAS)), physician global assessment (doctor's visual analogue scale (D-VAS)), Health Assessment Questionnaire Disability Index (HAQ-DI) score, C-reactive protein (CRP) level, erythrocyte sedimentation rate (ESR), matrix metalloproteinase-3 (MMP-3) level, rheumatoid factor (RF) value and anticyclic citrullinated peptide (CCP) antibody value were obtained from the patients' medical records.
Disease activity was assessed using the Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI). The cutoff values for remission, low disease activity (LDA), moderate disease activity (MDA) and high disease activity (HDA) were as follows: for remission, CDAI ≤2.8, SDAI ≤3.3; for LDA, 2.8 < CDAI ≤ 10, 3.3 < SDAI ≤ 11; for MDA, 10 < CDAI ≤ 22, 11 < SDAI ≤ 26; and for HDA, CDAI > 22, SDAI > 26 [18] .
Cell surface staining and flow cytometry analysis
Peripheral blood mononuclear cells (PBMCs) were obtained at baseline and at weeks 24 and 52 of TCZ treatment. PBMCs were separated by density gradient with Ficoll-Paque Plus (GE Healthcare, Uppsala, Sweden) and cryopreserved in CELLBANKER 1 (Nippon Zenyaku Kogyo, Fukushima, Japan) until use. Thawed cells were stained for 30 minutes at room temperature under darkened conditions with the following fluorophorelabeled mAbs: anti-CD4-VioGreen (Miltenyi Biotec, Bergisch Gladbach, Germany); anti-CD3-Pacific Blue/ fluorescein isothiocyanate (FITC), anti-CD8-Pacific Blue, anti-CD14-(APC)-Cy7, anti-CD20 allophycocyanin-cyanine 7 (APC-Cy7), anti-CD25 phycoerythrin (PE)-Cy5, anti-CD27-PE-Cy7, anti-CD38-PE-Cy5, anti-CD45RO-PECy7, anti-CD56-PE/PE-Cy7, anti-CD69-APC/PE-Cy7, anti-CD80-FITC, anti-CD86-PE-Cy5, anti-CD127-FITC, anti-CD161-APC, anti-chemokine (C-X-C motif ) receptor 3 (CXCR3)-PE and anti-HLA-DR-APC/APC-Cy7 (all from BD Biosciences, Franklin Lakes, NJ, USA); anti-CD16-Brilliant Violet 510 and anti-CCR6-Brilliant Violet 421 (both from BioLegend, San Diego, CA, USA); and anti-mouse immunoglobulin G isotype-matched controls (VioGreen from Miltenyi Biotec, the others from BD Biosciences).
Stained cells were washed twice with 2 ml of phosphatebuffered saline and analyzed on a MACSQuant analyzer (Miltenyi Biotec). Dead cells were confirmed with a propidium iodide fluorescence solution (Miltenyi Biotec) and excluded on the basis of scatter signals. The subsets analyzed were CD4 and CD8 T cells (including memory, effector and activation markers) and T H 1, T H 2, T H 17, T reg , B cells, natural killer cells, and monocytes, including their subpopulations and activation markers. The peripheral cell subsets identified in this study were defined by using cell surface markers on the basis of peripheral cell subsets described in a previous report (Additional file 1: Table S1 ) [19] .
Statistical analysis
Continuous data are presented as median and interquartile range (IQR) or as a number with percentage value, as appropriate. The Wilcoxon test and Kruskal-Wallis test were used to examine the differences between continuous variables. Correlation of two continuous variables was analyzed using the Spearman rank correlation coefficient. Fisher's exact test was used to compare the proportion of categorical data between groups. A P-value <0.05 was considered statistically significant. All statistical analyses were performed with JMP 10 (SAS Institute, Cary, NC, USA).
Results
Baseline characteristics of patients and associations between peripheral cell populations and disease activity at baseline Table 1 shows the baseline demographics and clinical characteristics of the enrolled patients (N = 39). In this population, there was no difference between TCZ monotherapy and TCZ in combination with MTX in terms of baseline characteristics.
At baseline, a higher proportion of HLA-DR + CD8 + T cells among the CD8 + T cells was significantly associated with higher CRP, Pt-VAS, SDAI and HAQ-DI, as well as a higher proportion of naïve and memory CD8 + T cells among the CD8 + T cells, was significantly associated with RF, ACPA, SJC, CDAI and SDAI (Additional file 1: Table  S2 ). A higher proportion of T H 2 cells among the CD4 + T cells was also significantly associated with TJC, D-VAS, Pt-VAS, CDAI and SDAI scores. No other baseline subsets or surface markers correlated with CDAI or SDAI score (Additional file 1: Table S3 ).
Changes from baseline in clinical response
All patients in this study received TCZ for the entire 52 weeks. The CDAI and SDAI scores (mean ± standard deviation) significantly decreased from 19.6 ± 9.3 and 21.1 ± 9.9, respectively, at baseline to 5.5 ± 5.2 and 5.5 ± 5.2 at week 24 and to 5.2 ± 6.0 and 5.6 ± 6.8 at week 52 (P < 0.0001). The number and percentage of patients categorized as having attained remission or as having LDA, MDA and HDA were as follows for CDAI and SDAI: at baseline, 0 (0%) and 0 (0%) for remission, 3 (7.7%) and 4 (10.3%) for LDA, 24 (61.5%) and 25 (64.1%) for MDA, and 12 (30.8%) and 10 (25.6%) for HDA, respectively; and at week 52, 21 (53.8%) and 22 (56.4%) for remission, 11 (28.2%) and 10 (25.6%) for LDA, 7 (17.9%) and 7 (17.9%) for MDA, and 0 (0%) and 0 (0%) for HDA, respectively (Additional file 1: Figure S2 ). (Tables 2 and 3 ). The other subsets and their activation markers were not significantly changed during TCZ therapy. Evaluation of the relationships between peripheral cell subsets and clinical response after tocilizumab therapy
Changes from baseline in peripheral cell subsets
Associations between changes in peripheral cell subsets and changes in clinical endpoints (ΔCDAI and ΔSDAI) after TCZ treatment are summarized in Table 4 . A significant correlation was observed between the change in the proportion of T reg cells among CD4 + T cells and the changes in CDAI score from baseline to week 52: the greater the increase in proportion of T reg cells among CD4 + T cells from baseline to week 52, the greater the improvement in CDAI score during the same period (ρ = −0.346, P = 0.031). Also, the change in CD38 
Association between the change in T reg cells and the effectiveness of tocilizumab therapy
The time course of changes in T reg cells as a proportion of CD4 + T cells is shown in Figure 1A . The median proportion of T reg cells significantly increased over 52 weeks from 3.6 (IQR, 2.2 to 4.3) to 5.6 (IQR 4.5 to 7.1) (P < 0.001). The change in CDAI and SDAI scores at week 52 was significantly associated with the change in T reg cells at week 52 (Table 4 , Figure 1B) . Of the 39 patients examined in this study, 21 (53.8%) met the CDAI criteria for remission and 22 (56.4%) attained SDAI remission at week 52. When we divided the patients into two groups according to their remission status at week 52, the change in peripheral blood T reg cells was significantly higher in the remission group than in the nonremission group at week 52 ( Figure 1C) . Moreover, the proportion of peripheral blood T reg cells was significantly higher in the remission group than in the nonremission group at week 52 ( Figure 1D ).
As for CD38 expression on CD8 + T cells, the overall expression did not change during 52 weeks (P = 0.913), and there was no difference in its proportion between the remission and nonremission groups at Week 52 (P = 0.453 for CDAI, P = 0.345 for SDAI).
Discussion
In this article, we report the results of the first comprehensive study to show the effect of TCZ on various peripheral cell subsets. In this study, we have shown that the proportion of CD4 + nonclassical monocytes significantly decreased from baseline. Among them, only the increase in T reg cells was significantly associated with achieving remission by TCZ treatment.
Related studies have reported the increase in T reg cell levels 1 year after TCZ administration in a small population [20] , for 3 months [15] and for 6 months [12] . Though definitions of T reg cells in our study, using only cell surface markers without stimulatory modification for cells in vitro, were different from those in these previous studies, our results showed the same trends as previously reported. The mechanism is a question that is not yet fully understood. However, this is still an important biomarker, as no suitable biomarker that can help predict outcome of RA has not been identified.
Several mechanisms may contribute to the potentiation of T reg cells by TCZ therapy. It is conceivable that IL-6 has an effect on T reg differentiation via inhibiting the expression of a specific transcriptional factor, FoxP3 [21, 22] . This may suggest a mechanism by which neutralizing of IL-6 signaling in patients with RA can induce an increase in the number and function of T reg cells. The quantitative increase in T reg cells expressing elevated levels of human leukocyte antigen (HLA)-DR in patients with RA treated with TCZ could also be a result of activation and proliferation of preexisting T reg cells or of their differentiation by conversion from Foxp3 − precursors. One question arising from the result is whether the increase of T reg proportion after TCZ therapy is a result of disease remission or is attributable to use of TCZ. To answer the question, we also analyzed peripheral T reg cells in 12 patients with RA longitudinally treated with MTX alone (Additional file 1: Table S4 ). All the patients achieved LDA or remission at week 52 after starting MTX therapy (Additional file 1: Figure S3 ). The proportion of T reg cells did not show a certain tendency or change over 52 weeks after administration of MTX (P = 0.729) (Additional file 1: Figure S4A ). In addition, the change in T reg cells at week 52 was not associated with the change in CDAI and SDAI scores at week 52 (Additional file 1: Figure S4B ). These results suggest that, albeit the comparison in a small number of patients with MTX, the increase in T reg proportion after TCZ therapy is not a result of disease remission but caused by TCZ therapy itself.
Another question is whether other biologic agents for RA treatment also induce T reg cells. It has been reported that neither adalimumab, an anti-tumor necrosis factor (anti-TNF) mAb, nor etanercept, a soluble TNF receptor, modified percentages or absolute numbers of circulating CD4 + CD25 high T reg cells or other T reg phenotypes after being administered for 6 and 12 weeks to patients with RA, regardless of their response [23] . However, there is one report that high concentrations of TNFα can block the immunosuppressive functions of T reg cells in vitro and that the treatment of patients with RA with infliximab, an anti-TNF mAb, bolsters T reg suppression of the proliferation of effector cells [24] . It is assumed that these conflicting results might be ascribed to a small number of subjects (N = 10 to 30) and a short observational period (12 to 24 weeks). Regarding abatacept, the therapy diminishes the absolute numbers of T reg cells but enhances their function in patients with RA [25] . It is conceivable that the different targets of these therapies influence the different performance of T reg cells and that the results of the present study indicate a part of the unique mechanism of TCZ.
Although much still remains to be clarified about how T reg defects might contribute to the pathogenesis of RA, approaches that specifically boost T reg activity could be + T cells at week 52. The squares signify medians and interquartile ranges, and the diamonds signify means and 95% confidence intervals. Data were analyzed by using the Kruskal-Wallis test (A), Spearman's rank correlation coefficient (B) and the Wilcoxon rank-sum test (C,D). *Significant differences.
useful in the treatment of RA. In this study, the change in T reg was correlated with disease activities after TCZ therapy. This is the first time that the effect of increasing T reg has been shown to be strictly associated with clinical efficacy.
The effects of IL-6 on the late stages of B cell differentiation in vitro are well documented [26] . In vivo IL-6 overexpression is associated with B cell hyperactivity, autoantibody production and immunopathology [27, 28] . In patients with RA, chronic activation of B cells and an accumulation of memory B cells in the peripheral blood and synovial membranes have been described [29, 30] . Within this context, B cell-targeted therapies utilizing rituximab have been widely explored in RA. Because IL-6 has been described as an important B cell-stimulating factor with effects on memory B cell survival and on plasma cell differentiation and survival in the bone marrow, it is easy to comprehend the effect of TCZ on peripheral B cells, especially the ratio of naïve B cells to memory B cells [31] . Although the proportion of memory B cells significantly decreased over 52 weeks of TCZ therapy, it did not correlate with any component of activity status, SJC, TJC, Pt-VAS, D-VAS, CRP and ESR. Therefore, the decrease can be attributed to the effect of TCZ therapy rather than to disease activity. When we compared the proportion of B cell subsets in the same 12 patients that were effectively treated with MTX alone during 52 weeks as mentioned above (Additional file 1: Table S5 ), we observed that the proportion of memory B cells tended to decrease in patients with MTX therapy, as in the case with TCZ, suggesting that the trend was not specific to TCZ therapy. However, the proportions of CD80 + and CD86 + B cells among all B cells did not change in patients who received MTX therapy. Therefore, the decrease in the proportion after TCZ therapy may be characteristic of TCZ.
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